Previous 10 | Next 10 |
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2022 Earnings Conference Call August 4, 2022 08:30 a.m. ET Company Representatives Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Direc...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of $0.21 misses by $0.09 . Revenue of $97.23M (-6.5% Y/Y) misses by $6.28M . Adjusted EBITDA was $56.0 million in the second quarter of 2022, compared to $65.2 million in the second quarte...
– LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year – – GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents – –...
Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.30 (-11.8% Y/Y) and the consensus Revenue Estimate is $103.51M (-0.5% Y/Y). Over the last 2 years, IRWD ...
Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is trading down 7% after AbbVie ( ABBV ) Friday morning reported Q2 2022 revenue of Linzess (linaclotide) -- which is marketed by both companies -- that came in below analyst consensus estimates. Linzess and Constella (...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 4, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. ...
DiDi Global DIDI +61% as Beijing looks to end cybersecurity probe. Yumanity Therapeutics YMTX+42% on all-stock merger with Kineta; lead product sale to J&J for $26M. Full Truck Alliance YMM +26% as Beijing looks to end cybersecurity probe. Kanzhun Limited BZ ...
Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600 Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...